"COG Addresses Unmet Needs In Pediatric NHL" - Angelica Welch
To address the unmet need of pediatric patients with non-Hodgkin lymphoma (NHL) who do not experience event-free survival (EFS) after chemotherapy, investigators from the Children’s Oncology Group (COG) are currently exploring several targeted therapies. Birte Wistinghausen, MD, medical director of the division of pediatric hematology-oncology at the Kravis Children’s Hospital at Mount Sinai, and a member of the COG Non-Hodgkin Lymphoma Committee, shared her insight on the potential for targeted therapies in the treatment of pediatric NHL, and the steps that COG is taking to cure all patients with this disease. “The take-home message is that our cure rates are good, but the work is not done. We believe that the only way to get the work done is to turn to targeted therapies, and that will take collaboration across institutions and groups. Hopefully, we can eventually reduce chemotherapy toxicity and exposure with targeted therapies,” Dr. Wistinghausen said.
- Birte Wistinghausen, MD, Medical Director, Division of Pediatric Hematology-Oncology, Kravis Children’s Hospital
Scientists Develop Novel Approach to Enhance Drug Delivery for Brain Tumors in Children
Mar 02, 2023 View All Press ReleasesMount Sinai Researchers Conduct Study of Second-Hand Marijuana Smoke in Children
Nov 19, 2018 View All Press Releases